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6/j.bThe subpopulation of regulatory T cells (Treg) was shown to play a key role in alloreactive responses. In
allogeneic hematopoietic stem cell transplantation, several groups tested whether Treg content in transplants
correlates with graft-versus-host disease (GVHD) with controversial results. In a retrospective study of 49
consecutive HLA-matched sibling transplantations, we studied the relationship between Treg content in
bone marrow transplants and acute GVHD (aGVHD) occurrence. We observed a large variability in Treg in
bone marrow grafts. However, contrary to previous observations in peripheral blood stem cells transplanta-
tion,we report that theTreg content of allogeneic bonemarrow transplantationdid not predict theoccurrence
of aGVHD.
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studyINTRODUCTION
CD41CD251FoxP31 regulatory T cells (Treg)
have an important role in the control of alloreactivity
in allogeneic stem cells transplantation [1]. The first
direct demonstration of Treg immunosuppressive ef-
fect on alloreactivity was made in experimental bone
marrow (BM) transplantation (BMT) in mice, where
complete Treg depletion before grafting significantly
accelerated the mortality linked to graft-versus-host
disease (GVHD) [2,3]. These observations led to the
study of Treg content in transplants as a predictive
factor for GVHD in humans. However, despite
increasing evidences that Treg content could haveversite´ Pierre et Marie Curie-Paris 6, Paris, France,
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bmt.2010.07.024diagnostic and prognostic value for acute GVHD
(aGVHD)when assessed in grafted patients [4], clinical
studies were never performed in BM transplants and
remain controversial in peripheral blood stem cell
(PBSC) transplants (for review, see [5]).
Here, we studied the relationship between Treg
content in nonmanipulated BM transplants and
aGVHD occurrence in a retrospective study of 49
consecutive HLA-matched sibling transplantations.MATERIALS AND METHODS
Patients
Forty-nine consecutive patients transplanted graf-
ted at the Pitie´ Salpeˆtrie`re Hospital between February
2000 and July 2008, with BM from HLA-matched
sibling donors, were included in this single center
retrospective study. Written informed consent was ob-
tained from all donors prior to sampling. The institu-
tional review board ‘‘Ile-de-France IX’’ reviewed and
approved the study.
Acute GVHD (grade II to IV) defined according to
published criteria [6], has occurred in 65% (32 of 49) of
the patients. All patients received a myeloablative con-
ditioning regimen (total body irradiation [TBI] and
high-dose cyclophosphamide or high-dose cyclophos-
phamide plus busulfan) and GVHD prophylaxis with
a short course of methotrexate (15 mg/m2 on day 1,
10 mg/m2 on day 3, and 10mg/m2 on day 6) and cyclo-
sporine. They all engrafted successfully. Grade II-IV265
Table 1. Candidate Variables in Cox’s Model Analysis of Time to acute GVHD
Acute GVHD Univariate Cox model analysis
Variables No (n 5 17) Yes (n 5 32) HR [95% CI]*
D/R gender: number of female/male (%) 3 (17.7) 8 (25.0) 1.35
CMV status donor/recipient 2/2 (%) 5/17 (29.5) 8/31 (25.8) 1.08
Complete remission at HSCT (%) 7/14 (50.0) 15/31 (48.39) 0.97
Age of recipients (year): median [range] 41 [21-53] 40 [17-55] 1.005 [0.97-1.04]
Age of donors (year): median [range] 37 [12-60] 39 [12-62] 1.01 [0.99-1.04]
CD34+/kg  106: median [range] 2.56 [0.76-5.46] 1.80 [0.81-5.93] 0.96 [0.69-1.28]
CD3+/kg  107: median [range] 2.79 [1.52-5.30] 3.14 [0.18-8.40] 5.21 [0.54-44.2]
CD3+CD4+/kg  107: median [range] 1.26 [0.62-2.66] 1.55 [0.11-2.88] 2.24 [0.42-11.4]
CD4+CD25high/kg  105: median [range] 3.32 [0.79-14.77] 4.64 [0.42-9.46] 1.00 [0.89-1.10]
CD4+Foxp3+/kg  105: median [range] 2.07 [0.50-14.54] 3.16 [0.40-10.53] 1.01 [0.90-1.11]
CD25high/CD3 (%): median [range] 1.21 [0.45-3.98] 1.37 [0.48-2.73] 0.97 [0.70-1.30]
Foxp3/CD3 (%): median [range] 0.97 [0.17-3.72] 0.95 [0.21-2.83] 0.99 [0.72-1.31]
GVHD indicates graft-versus-host disease; CMV, cytomegalovirus; D/R, donor/recipient; HSCT, hematopoietic stem cell transplant; HR, hazard ratio; CI,
confidence interval.
Forty-nine patients were grafted for acute leukemia (n5 18), lymphoma or chronic lymphocitic leukemia (n5 16), multiple myeloma (n5 3), or other
diseases (n 5 12). Twenty-two patients were in complete remission at time of transplantation. The patient population was broken down according to
acute GVHD outcome (grade II to IV). For quantitative variables, groups (aGVHD yes versus no) were compared with the Mann-Whitney test, and for
qualitative ones with the Fisher exact test. No comparisons achieved the statistical significance threshold (P(a 2-sided) < .05).
*Univariate Cox (proportional hazards model) regressions of time to aGVHD (rightmost column) were performed for the candidate variables in the
table. Data in cells are Hazard Ratio [95% confidence intervals].
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with anti-rIL2 (n 5 5) or mycophenolate mofetil
(n 5 3) or both (n 5 1).
BM Analysis
The concentration (cells/mL)ofT lymphocyteswas
established from fresh bone marrow samples with
a 3-color flow cytometry using BD Multitest (CD3/
CD19/CD45)withTrucount tubes containing fluores-
cents beads as internal standard (BD Biosciences,
Mountain View, CA). Treg analysis was performed
on BM sample aliquots after thawing. No difference
before and after cryopreservation/thawing was
observed (Figure S1). Intranuclear forkhead box P3
(FoxP3) labeling was performed after CD3 (Clone
UCHT1 Beckman Coulter, Villepinte, France), CD4
(Clone SFC12T4D11) and CD25 (Clone M-A251;
BD Biosciences) membrane staining using antihuman
Foxp3 kit (PCH101 clone, eBioscience, San Diego,
CA), with rat IGg2a isotypic control. Cells acquisition
and analysis was performed on a FacsCalibur cytome-
ter using CellQuest software (BD Biosciences).
Statistical Analysis
AMann-Whitney test was used to compare clinical
and biologic characteristics in patients with aGVHD
versus patients who did not experience aGVHD. Uni-
variate and multivariate Cox model regression analysis
of time to aGVHD was used to evaluate the influence
of each candidate prognostic factor on the risk of
aGVHD.Data were analyzed using JMP software (ver-
sion 8.0; SAS Institute Inc., Cary, NC), and statistical
threshold for significance set atP(a 2-tailed)\.05. Sample
size was calculated based on the 3 previous studies and
powered to detect a similar difference [6-8]. Wecalculated that with our cohort (aGVHD, n 5 32; no-
aGVHD, n5 17), the power was .80% (at p(a 1-tailed)
\.05) to detect a 60% increase in the bone marrow
graft Treg content in the no-aGVHD group versus
aGVHD1 (by the t-test) [6], or to detect a 35% increase
in aGVHD-free survival in high-Treg versus low-Treg
group (by the log-rank test) [7,8].RESULTS AND DISCUSSION
Following BMT, 32 (65%) patients developed an
aGVHD (grade II, n 5 24, grade III-IV, n 5 8). Cox
regression analysis showed a trends in increase in
aGVHDriskwith increasingCD31Tcell graft content
(HR [95% CI] 5 0.21 [0.54-44.2]). None of the other
candidate variables were found to have a statistical sig-
nificance either in group comparisons or as prognostic
factors inCoxmodel analysis (Table 1).Tregwere iden-
tifiedby eitherCD25high orFoxP3 expression onCD41
T cells (Figure 1A) with a good correlation (r 5 0.85)
between these 2 markers (Figure S2). Analysis of Treg
numbers revealed a large variability within the donor
population (mean 5 4.85  105/kg 6 3.08 for CD25
and3.72 105/kg6 3.13 for FoxP3) (Figure 1B).How-
ever, no correlation between occurrence of aGVHD
and the proportion or absolute number of infused
Treg was found (regardless of aGVHD grades cutoff
point used; 0-I versus II-IV in Figure 1B, but also 0 ver-
sus I-IV or 0-II vs III-IV, data not shown). Overall
aGVHD-free survival was not statistically different
in patients who received above or below the median
graft Tregs (median CD251 count 5 4.25  105/kg)
(Figure S3). The analysis of the Treg ratio to CD31
T cells yielded similar results. In the entire cohort,
CD3 and Treg content were significantly correlated
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Figure 1. Regulatory T cell content of the grafts does not correlatewith incidence of GVHD. (A) FACS plots showing the gating criteria used to quantify
regulatory T cells upon CD41CD25hi and CD41FoxP31 phenotypes. (B) Scatter plot showing the percentage (up) or the absolute number (low) of
infused Treg with respect to the grade of GVHD. Horizontal bars represent the mean. Mean % of CD25high 5 3.25 6 0.0.49 for the no GVHD group
and 3.16 6 0.22 for the aGVHD group; mean % of CD41FoxP31 5 2.51 6 0.51 for the no GVHD group and 2.45 6 0.26 for the aGVHD group;
mean number of CD25high 5 4.85 6 1.02  105/kg for the no GVHD group and 4.84 6 0.41  105/kg for the aGVHD group; mean number of
CD41FoxP31 5 3.676 0.98  105/kg for the no GVHD group and 3.736 0.45  105/kg for the aGVHD group.
Biol Blood Marrow Transplant 17:265-269, 2011 267Treg in Donor’s Bone Marrow Do Not Predict GVHD(r25 .22,P5 .0007, and r25 .15,P5 .006, for CD251
and Foxp31, respectively). A multivariate Cox model
analysis showed that Treg content was not an indepen-
dent predictor (CD25, P 5 .18; CD3 P 5 .01) of
aGVHD even following adjustment for CD3 content.
We thus conclude that, in contrast to previous observa-
tions in PBSC transplantation, our results do not sup-
port the usefulness of assessing allogeneic BM Treg
content to predict aGVHD.However, given the limited
dimension of these cohorts we cannot rule out an effect
of smaller magnitude. As a consequence, our conclu-
sions probably need to be confirmed in a larger sample.
Three previous studies [7-9] showed that a high
level of Treg in donor peripheral blood was associated
with reduced cumulative incidence of aGVHD in
cohorts of 22, 63, and 34 patients, respectively. In 1 of
these studies Treg measurement was performed before
granulocyte-colony stimulating factor (G-CSF) admin-
istration [7], whereas it was performed after for the 2
remaining. These results were observed both in related
and unrelated PBSCmyeloablative transplantations butnot with reduced-intensity conditioning (RIC). In addi-
tion, these studies focused on absolute numbers of
Treg but not on the percentage of Treg among CD31
or CD41 T cells within graft, which is a determinant
parameter regarding the suppressive effect of Treg [10].
The source ofHSC (PBSCversusBM)may also im-
pact the Treg content as recently observed by Blache
et al. [11], and consequently, relationship between the
Treg content of the transplant and the risk of aGVHD
[12,13]. In our study involving BM only, patients
received about 10-fold fewer CD31 T cells compared
with studies performed with PBSC [8,9]. Despite
a similar incidence of aGVHD observed in these 2
settings, it remains possible though highly speculative,
that Treg variation may have more relevance when
increased numbers of T cells are injected. In addition,
CD3 and Treg should have a dual and opposite effect
on the risk of aGVHD, although both are linearly
related as shown by the high correlation in our study.
Hence, the modeling of the effect of the variation of
these 2 parameters on the risk of aGVHD is likely to
268 Biol Blood Marrow Transplant 17:265-269, 2011M. Rosenzwajg et al.be nonlinear. Indeed, in our study as in Pabst et al. [8,9],
in multivariate analysis, Treg is not an independent
predictor of the risk of aGVHD.
Finally, G-CSF treatment may have modified the
Treg content and/or the rate of GVHD occurrence.
Unfortunately, the impact of G-CSF on T cells is not
entirely understood [11,14,15]. Our study has the
advantage that neither donors nor recipients were
treated with G-CSF, thereby avoiding a possible
confounding factor.
The hypothesis that the Treg graft content may be
related to GVHD occurrence originated from mouse
experiments. Notably, accelerated GVHD was ob-
served only when the transplant was fully Treg depleted
[2,3], and protection against GVHD was only achieved
when using Treg at the very high ratio of 1:1 Treg to
conventional CD41 T cell [2,3,16-19]. Despite the
substantial variation in Treg concentration among
donors (near 1 log in our study), the mean ratio of
Treg to conventional CD41 T cells (1:35 in BM
samples) is far lower than the 1:1 ratio required for
a therapeutic effect in murine models. Consequently,
the impact of variations of Treg content that we
observed in nonmanipulated human transplants may
be of lesser significance. However, in the absence of
correlation in this study and based on previous studies
in mice, it may be worthwhile to manipulate Treg
to a greater degree than that which occurs naturally.
aGVHDmay be attenuated or prevented by increasing
the ratio of Treg in the transplant. Alternatively, Treg
depletion may improve the graft-versus-tumor (GVT)
effect of donor lymphocytes [20]. We have recently
successfully tested this approach in a clinical trial which
demonstrates thatTreg depletion is a safe approach that
induces GVHD and antitumoral effect in patients
not responding to a classical donor lymphocyte infusion
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